<ENAMEX TYPE="ORGANIZATION">Marion Laboratories Inc.</ENAMEX> said it named six <ENAMEX TYPE="ORGANIZATION">Dow Chemical Co.</ENAMEX> executives to its board as part of a previously announced agreement to combine <ENAMEX TYPE="ORGANIZATION">Marion</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">Dow</ENAMEX>'s Merrell <ENAMEX TYPE="ORGANIZATION">Dow Pharmaceuticals</ENAMEX> subsidiary.
The pharmaceutical concern said the addition of the six new members will bring its board membership to 15. The directors will serve on an interim basis until its shareholders approve a slate to be presented at the annual meeting, to be held on Nov. 9.
The new board members are <ENAMEX TYPE="PERSON">Frank P. Popoff</ENAMEX>, president and chief executive of <ENAMEX TYPE="ORGANIZATION">Dow</ENAMEX>; <ENAMEX TYPE="PERSON">Keith R. Mckennon</ENAMEX>, executive vice president; <ENAMEX TYPE="PERSON">Enrique C. Falla</ENAMEX>, vice president and chief financial officer; <ENAMEX TYPE="PERSON">Joseph G. Temple Jr.</ENAMEX>, chairman and chief executive of Merrell <ENAMEX TYPE="ORGANIZATION">Dow</ENAMEX>; <ENAMEX TYPE="PERSON">David B. Sharrock</ENAMEX>, president and chief operating officer of Merrell <ENAMEX TYPE="ORGANIZATION">Dow</ENAMEX>; and <ENAMEX TYPE="PERSON">Walter M. Lovenberg</ENAMEX>, president of Merrell <ENAMEX TYPE="ORGANIZATION">Dow Research Institute</ENAMEX>.
<ENAMEX TYPE="PERSON">Marion</ENAMEX> said the transaction to merge the two companies is expected to be completed in November.
